Enovis (NYSE:ENOV) Rating Increased to Strong-Buy at Wells Fargo & Company

Enovis (NYSE:ENOV) was upgraded by research analysts at Wells Fargo & Company to a “strong-buy” rating in a report released on Wednesday,Zacks.com reports.

Several other equities analysts have also commented on the stock. BTIG Research increased their price target on shares of Enovis from $41.00 to $43.00 and gave the company a “buy” rating in a research note on Thursday, February 26th. UBS Group restated a “buy” rating and set a $50.00 price objective on shares of Enovis in a research report on Monday, January 5th. Needham & Company LLC upped their target price on shares of Enovis from $49.00 to $52.00 and gave the company a “buy” rating in a report on Thursday, February 26th. Canaccord Genuity Group dropped their target price on shares of Enovis from $58.00 to $50.00 and set a “buy” rating on the stock in a research report on Wednesday, December 17th. Finally, Wall Street Zen upgraded shares of Enovis from a “hold” rating to a “buy” rating in a research note on Saturday, March 14th. Two equities research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $47.43.

Enovis Stock Down 2.1%

Shares of NYSE ENOV opened at $22.97 on Wednesday. The business has a 50-day moving average of $23.55 and a two-hundred day moving average of $27.64. The company has a market capitalization of $1.31 billion, a price-to-earnings ratio of -1.11 and a beta of 1.46. Enovis has a 1 year low of $21.00 and a 1 year high of $40.69. The company has a debt-to-equity ratio of 0.85, a current ratio of 2.02 and a quick ratio of 1.04.

Enovis (NYSE:ENOV) last released its quarterly earnings data on Thursday, February 26th. The company reported $0.95 EPS for the quarter, beating analysts’ consensus estimates of $0.81 by $0.14. Enovis had a positive return on equity of 8.74% and a negative net margin of 52.69%.The business had revenue of $575.76 million for the quarter, compared to the consensus estimate of $584.30 million. During the same quarter in the prior year, the business posted $0.98 EPS. The business’s revenue for the quarter was up 2.6% on a year-over-year basis. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. On average, analysts forecast that Enovis will post 2.79 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Enovis news, insider Oliver Engert bought 1,000 shares of Enovis stock in a transaction dated Friday, February 27th. The stock was acquired at an average cost of $25.50 per share, with a total value of $25,500.00. Following the completion of the acquisition, the insider owned 43,640 shares of the company’s stock, valued at approximately $1,112,820. This represents a 2.35% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have acquired 5,000 shares of company stock valued at $121,983 in the last quarter. Insiders own 2.70% of the company’s stock.

Hedge Funds Weigh In On Enovis

Hedge funds and other institutional investors have recently made changes to their positions in the stock. River Road Asset Management LLC increased its position in Enovis by 3.2% in the 4th quarter. River Road Asset Management LLC now owns 1,487,277 shares of the company’s stock valued at $39,621,000 after acquiring an additional 46,289 shares during the period. Corient Private Wealth LLC lifted its position in Enovis by 540.7% during the 4th quarter. Corient Private Wealth LLC now owns 55,180 shares of the company’s stock worth $1,470,000 after acquiring an additional 46,568 shares during the period. Front Street Capital Management Inc. grew its stake in shares of Enovis by 75.8% in the 4th quarter. Front Street Capital Management Inc. now owns 361,932 shares of the company’s stock valued at $9,642,000 after purchasing an additional 156,069 shares during the last quarter. XTX Topco Ltd purchased a new position in shares of Enovis in the 4th quarter valued at approximately $561,000. Finally, Susquehanna Portfolio Strategies LLC increased its holdings in shares of Enovis by 249.9% in the fourth quarter. Susquehanna Portfolio Strategies LLC now owns 140,997 shares of the company’s stock valued at $3,756,000 after purchasing an additional 100,704 shares during the period. Hedge funds and other institutional investors own 98.45% of the company’s stock.

Enovis Company Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.